BI 3819026 + Ezabenlimab for Cancer

This trial seeks to determine the highest dose of a new medicine, BI 3819026, that individuals with advanced cancer can safely tolerate. The study evaluates BI 3819026 both alone and in combination with ezabenlimab, an immunotherapy drug, both of which may aid in fighting cancer. Participants must have advanced cancer that has progressed after or resisted standard treatments. Initially, they will receive BI 3819026 alone, followed by the combination with ezabenlimab, and must visit the study site regularly for up to two years. This trial suits those with cancer that has spread and is unresponsive to other treatments. As a Phase 1 trial, this research focuses on understanding how the treatment works in people, offering participants the chance to be among the first to receive this new treatment.

The trial protocol does not specify if you need to stop taking your current medications. However, you must not have had systemic anti-cancer drugs within 3 weeks or 5 half-lives before starting the trial treatment, and you must be off steroids and anti-convulsive drugs for at least 7 days before the first administration of BI 3819026.

Previous studies have shown that ezabenlimab is safe for patients with advanced solid tumors, with no severe side effects preventing continuation of treatment. Common side effects included fatigue, nausea, low red blood cell count, and decreased appetite. These side effects are manageable and often expected with cancer treatments.

Researchers are excited about BI 3819026 and Ezabenlimab for cancer because these treatments offer a fresh approach to targeting tumors. Unlike traditional options such as chemotherapy, which attacks both cancerous and healthy cells, BI 3819026 and Ezabenlimab are designed to boost the immune system's ability to fight cancer cells more precisely. Ezabenlimab is a PD-1 inhibitor, a type of immunotherapy that helps the immune system recognize and destroy cancer cells. This targeted mechanism may lead to fewer side effects and potentially more effective results, offering hope for patients looking for new cancer treatment options.

Research has shown that ezabenlimab, a medicine that enhances the immune system, is generally safe and can help combat various cancers. It improves the immune system's ability to attack cancer cells. Earlier tests found ezabenlimab to be safe and effective over the long term for many patients. In this trial, participants will receive a combination of ezabenlimab and BI 3819026, which researchers are still studying for effectiveness. This combination aims to offer a new treatment for advanced cancers by strengthening the body's natural defenses.¹²³⁴⁵